EGFR与ErbB2双重酪氨酸激酶抑制剂拉帕替尼二甲苯磺酸酯的研究进展.pdfVIP

Ch nese Journal of N ew D rugs 2007, V ol. 16 N o. 23 2007 16 23 EGFR Er bB2 1 2 , ( 1 卫生部北京医院药学部临床药理室, 北京 100730; 2 广西工业职业技术学院, 南宁 530001) [ ] 拉帕替尼是一种人源 2 表皮生长因子受体( HER 2) 和表皮生长因子受体( EGFR ) 双重酪氨酸激酶 抑制剂, 与卡培他滨联用治疗女性HER 2阳性的乳腺癌我们利用M EDL INE 进行关键词为拉帕替尼的文献检索, 对其药理作用药动学临床疗效及安全性, 药物相互作用等进行综述 [ ] 拉帕替尼二甲苯磺酸酯; 酪氨酸激酶抑制剂; 乳腺癌 [ ] R979. 1 [] B [] 1003- 37 34 ( 2007) 23- 1990 - 04 Advance in research for lapatinib, a dual inhibitor of EGFR and ErbB2 tyrosine kinase activity 1 2 FENG Y u-fe , ZEN G Chun- lan ( 1D ep artm en t of C linical Pharmacology, B eij ing H osp ital, B eij ing 100730, China; 2 Guangx i Vocational Technical nstitu te of ndustry, N anning 530001, China ) [Ab stract L apat n b s a tyros ne k nase nh b tor of hum an ep derm a l grow th factor receptor type 2 ( HER2 or HER2 / neu) and ep derm al grow th factor receptor ( EGFR) . It s act ve n com b nat on w th capec tab ne n treatm ent o f w om en w th HER2-pos t ve m etastat c breast cancer that has progressed after trastuzum ab-based therapy. A l terature search w as conducted by M EDL INE u s ng the key w ord lapa- t n b. Its pharm aco logy, pharm acok net cs, eff cacy, safety and drug nteract ons n the treatm ent o f breast cancer are rev ew ed n th s paper. [Key w ord s lapat n b d tosylate; tyros ne k nase nh b tor; breast cancer ( lapat n b d tosy late, 1 [ 1 ~ 8 : T ykerb) ( EGFR ) , 2007 3 ( RTK s) , RTK s 13 ( FDA ), 2 RTK s( ( H ER2) ) ,